Major depression is a highly complex disabling psychiatric disorder affecting millions of people worldwide. Despite the availability of several classes of antidepressants, a substantial percentage of patients are unresponsive to these medications. A better understanding of the neurobiology of depression and the mechanisms underlying antidepressant response is thus critically needed. We previously reported that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) exhibit a depressive-like phenotype and a blunted antidepressant response to the selective serotonin reuptake inhibitor fluoxetine. In this study, we similarly 
Introduction
Mood disorders (including major depressive disorders and bipolar disorders) are a major cause of disability worldwide, with an estimated lifetime prevalence of 16% (Kessler et al., 2005) .
Although the underlying etiological mechanisms are complex and still unclear, studies over the past decades have highlighted the importance of the transcription factor cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) and one of its target genes brain-derived neurotrophic factor (Bdnf) (Blendy, 2006; Krishnan and Nestler, 2008; Martinowich et al., 2007) . CREB is a pleiotropic transcription factor involved, in particular, in neuronal growth and survival, neurogenesis, synaptic plasticity and long-term memory (Blendy, 2006; Carlezon et al., 2005; Lonze and Ginty, 2002) . BDNF is also implicated in these processes, partly through the induction of its expression by CREB (Martinowich and Lu, 2008; Martinowich et al., 2007) . CREB and BDNF have both been involved in depression and antidepressant treatment. Indeed, overexpression of CREB and BDNF in the hippocampus (HIP) results in antidepressant effects (Chen et al., 2001; Shirayama et al., 2002) and inversely, chronic stress reduces Bdnf expression in the same structure (Smith et al., 1995) . Of note, antidepressants such as fluoxetine and desipramine were also shown to upregulate Bdnf expression in the prefrontal cortex (PFC) and HIP of rodents in a CREB-dependent manner (Conti et al., 2002) .
CREB-regulated transcription coactivator 1 (CRTC1) is a potent CREB coactivator activated by cAMP and Ca 2+ signaling that trigger its dephosphorylation and translocation to the nucleus, where it binds to CREB, helps to recruit CREB-binding protein (CBP) and RNA polymerase II, and thus activates CREB-dependent gene transcription ( Altarejos and Montminy, 2011; Ch'ng et al., 2012; Conkright et al., 2003; Kovacs et al., 2007; Ravnskjaer et al., 2007; Screaton et al., 2004) .
CRTC1 is involved in activity-induced dendritic growth and late phase long-term potentiation (L-LTP) (Kovacs et al., 2007; Li et al., 2009; Zhou et al., 2006) . Moreover, Bdnf expression as well as BDNF-dependent dendritic growth require CRTC1 (Finsterwald et al., 2010; Kovacs et al., 2007; Zhou et al., 2006) . Region-specific CRTC1's activation is critical for activity-dependent immediate early genes regulation and long-term fear memory (Nonaka et al., 2014a; Sekeres et al., 2012) . CRTC1-dependent transcription of Bdnf and orphan nuclear receptors 4a (Nr4a) is also involved in cognitive impairments related to Alzheimer's disease (Parra-Damas et al., 2014) .
To further investigate the role of CRTC1 in the brain, we generated a CRTC1-deficient mouse line that exhibits several endophenotypes related to mood disorders and a blunted response to the antidepressant fluoxetine in behavioral despair-related paradigms (Breuillaud et al., 2009; Breuillaud et al., 2012) . At the molecular level, Crtc1 -/-mice have a decreased HIP and PFC expression of several CREB-regulated neuroplasticity genes, including notably Bdnf and Nr4a1-3 (Breuillaud et al., 2012) . Altogether, this suggests that CRTC1, as a key regulator of neuroplasticity-related genes, is critical for mood regulation and antidepressant response.
However, the direct or indirect mechanisms linking CRTC1's deficiency and behavioral consequences are still unclear. As CRTC1 promotes CBP recruitment, which has an intrinsic histone acetyltransferase (HAT) activity, these mechanisms might include CRTC1-related epigenetic gene regulation. Noteworthily, epigenetic mechanisms have been widely associated with depressive disorders and with CREB and Bdnf regulation in the frame of stress and antidepressant response Tsankova et al., 2007; Tsankova et al., 2006; Vecsey et al., 2007; Vialou et al., 2013) .
In this study, we were interested in further investigating the involvement of CRTC1 in antidepressant response and the underlying molecular mechanisms. We first tested the effects of chronic desipramine on the behavior of Crtc1 -/-mice, which revealed a blunted behavioral response to this antidepressant. We also observed that desipramine failed to induce Bdnf and Nr4a1-3 expression in the HIP and PFC of Crtc1 -/-mice. By acting at the epigenetic levels and treating the animals with a HDAC inhibitor, we were able to partially rescue the depressive-like behavior of Crtc1 -/-mice. This was paralleled by an increased expression of Bdnf, but not Nr4a1-3, in the PFC of these animals.
Materials and Methods

Animals
Crtc1 -/-mice and wild-type (WT) littermates were generated and genotyped as previously described (Breuillaud et al., 2009 ). Mice were housed under a 12-h light-dark cycle with ad libitum access to water and standard rodent chow diet. Male mice were weaned at 21 days and group-housed until being isolated at 5 weeks of age in order to avoid wounding of cage mates by aggressive Crtc1 -/-males (Breuillaud et al., 2012) . All animal experiments were conducted in accordance with the Swiss Federal Veterinary Office's guidelines and were approved by the Cantonal Veterinary Service. Behavioral procedures began when mice reached the age of 8 weeks.
Drugs and treatment
Desipramine hydrochloride was purchased from Sigma (St-Louis, MO, USA). Mice received desipramine in the drinking water at a concentration of 100 mg/l, which corresponds to approximately 20 mg/kg of body weight/day. Desipramine solution was changed every week and concentration was adjusted depending on the weight gain and average water consumption of the mice. Suberoylanilide hydroxamic acid (SAHA, also known as vorinostat) was purchased from Selleck Chemicals (Houston, TX, USA). Mice received SAHA through daily intra-peritoneal injections. SAHA was first dissolved in DMSO at a dose of 50 mg/ml. This stock solution was diluted 1:10 every day in saline solution (final concentration: 5 mg/ml) prior to injections at a dose of 25 mg/kg of body weight. Vehicle groups were injected with a solution of 10% DMSO in saline.
Repeated open-space forced swim procedure (OSFS)
The repeated OSFS procedure was performed as previously described (Breuillaud et al., 2012; Stone and Lin, 2011) . Briefly, swimming was carried out in rat tub cages (24x43x23 cm) filled with ~14 cm of lukewarm tap water (34±0.5°C) and colored with ~10 ml of milk. Mice undertook individual daily swim of 15 minutes during 4 consecutive days (Days -4 to -1). On day 0, desipramine or SAHA treatment started. Swimming sessions were repeated at 3 or 4 days of intervals during 3 weeks (Days 2, 5, 9, 12, 16, 19, 23) under continuous treatment (Fig. 1A) .
Water was changed after 4 mice had swum, in order to maintain water temperature. Swimming sessions were videotaped from above. Time spent immobile (drifting with no observable movement of limbs or tail) was manually recorded.
Novelty-induced hypophagia (NIH)
NIH procedure started on day 24, one day after the last swimming session (Fig. 1A ). Mice were trained to drink sweetened condensed milk (1:3, condensed milk: water) for two consecutive days (day 24 and 25), 2x1h each day. Milk was presented in homemade drinking tubes made of 10 ml conical tubes (Sarsedt) with a hole at the bottom closed by a glass bead (5 mm diameter)
to make a sipper. Tubes were placed through wire cage lids. On the third day (day 26), mice were tested in homecage conditions (light intensity: ~27 lux). Mice were videotaped during 15 min from the side and latency to drink was measured. On the fourth day (day 27), mice were placed in a novel cage without bedding, under bright light (~1200 lux), and the same measurements were made. The cage was cleaned with water and 70% ethanol between each mouse and before the first mouse.
Brain microdissection and micropunching
On day 28, one day after the end of the NIH procedure, all mice were sacrificed by cervical dislocation and decapitation. The brain was rapidly placed in a stainless steel adult mouse brain slicer matrix with 1 mm coronal section slice intervals. Six coronal slices were made from the second frontal slice channel of the matrix. Brain slices were placed on microscope slides and immediately frozen in dry ice, and then stored at -80°C. Medial PFC and dorsal HIP were collected with a micropunch (ø 1 mm, Stoelting, Wood Dale, IL, USA) in corresponding brain slices. PFC and HIP samples were kept at -80°C.
Gene expression analysis
Total RNA was extracted and purified from the PFC and HIP micropunches, using the RNAeasy Plus Minikit (Qiagen, Venlo, Netherland) according to the manufacturer's instructions. RNA concentrations were measured by UV spectrophotometry with a NanoDrop Lite (Thermo Scientific, Wilmington, DE, USA). cDNA was prepared in a 50 μl reaction by reverse transcription, using 100 ng of RNA with Taqman 
Effects of SAHA on histone acetylation
Mice were weaned and housed according to 2. Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween-20], supplemented with 5% skim milk powder.
Blots were subsequently incubated with a primary antibody in TBST plus 5% bovine serum albumin (BSA) overnight at 4°C. Finally, PVDF membranes were incubated for 1 hour at RT with horseradish peroxidase (HRP)-conjugated secondary antibodies in TBST plus 5% skim milk powder, and developed using a Pierce ECL Western chemiluminescence detection kit (Thermo 
Statistical analyses
Statistical analyses were performed using the Statistica 8.0 Software (StatSoft Inc., Tulsa, OK, USA). All data are presented as mean ± SEM. P-values of p < 0.05 were considered as statistically significant. A Shapiro-Wilk test was first performed to assess data normality. All results were found to follow normal distribution; therefore parametric tests could be used. For both behavioral and molecular analyses, a two-way ANOVA was performed to assess statistical differences for two factors (genotype and treatment). A Fisher LSD post-hoc test was carried out afterwards. For analyses of the OSFS data, a two-way ANOVA with repeated measures was performed as immobility time was repeatedly measured. A Fisher LSD post-hoc test was carried out afterwards.
Results
Crtc1 -/-mice have a blunted behavioral response to chronic desipramine treatment
Behavioral effects of desipramine were first assessed in the open-space forced swim (OSFS) model of depression ( Fig. 1A and 1B ). This protocol induces depressive-like symptoms that are reversed by chronic, but not acute, antidepressant treatments, and thus it has better face and construct validities than the conventional forced swim test (Breuillaud et al., 2012; Stone and Lin, 2011; Stone et al., 2008) . All animals presented increased immobility time after the four days of consecutive swimming with a significant effect of time (F (1,37) =36.1, p<0.001) and genotype (F (1,111) =13.7, p<0.001). Crtc1 -/-mice had higher immobility time than WT mice during the last two sessions of the pre-test period (day -2 and -1) (p<0.001 for both days). This genotype effect remained significant after the beginning of the desipramine treatment (F (1,35) =71.34, p<0.001), indicating that Crtc1 -/-mice had higher immobility time that WT mice during the whole procedure. WT mice progressively responded to desipramine, as their immobility time significantly decreased over time. As compared to their own immobility time on day 2 of treatment, the effect of desipramine became significant starting from day 9 (p=0.029 on day 9, p=0.003 on day 12, p<0.001 on days 16, 19 and 23, vs. day 2). Their immobility time was also lower than untreated WT mice, starting from day 9 as well (p=0.032 on day 9, p=0.032 on day 12, p=0.023 on day 12, p=0.016 on day 19, p=0.009 on day 23, vs. WT untreated). Desipramine had no effect on the depressive-like behavior of Crtc1 -/-mice, indicating that these mice were resistant to desipramine in this paradigm. At the end of the procedure, mice were then tested in the novelty-induced hypophagia (NIH) test, a depressionand anxiety-related paradigm sensitive to chronic antidepressant treatment (Dulawa and Hen, 2005) (Fig. 1A and 1C ). In homecage conditions, genotype or treatment had no effect on the latency to consume condensed milk, whereas a significant effect of desipramine was found in the novel environment (F (1,30) =6.52, p=0.016). Desipramine significantly decreased the latency of Crtc1 -/-mice (p=0.005, vs. untreated Crtc1 -/-mice), thus showing that these mice responded positively to desipramine in this paradigm. Comparably to their response to fluoxetine (Breuillaud et al., 2012) , Crtc1 -/-mice show a blunted response to chronic desipramine in the OSFS test and a reduced latency to drink sweetened milk in the anxiogenic environment of the NIH, which suggest a differential involvement of CRTC1 in the behavioral response to antidepressants.
Desipramine fails to induce expression of neuroplasticity-related genes in Crtc1 -/-mice
In order to investigate the molecular mechanisms underlying the blunted behavioral response of Crtc1 -/-mice to desipramine, gene expression analysis was performed in the HIP and PFC of these animals ( Fig. 2) . Crtc1 -/-mice have a reduced expression of several neuroplasticityrelated genes in these brain regions involved in depressive disorders (Breuillaud et al., 2012) .
We were first interested in assessing a possible effect of desipramine on Crtc1 expression in WT mice ( Fig. 2A) . Desipramine upregulated Crtc1 mRNA in the PFC of WT mice (t=-2.35, df=12, p=0.037, vs. WT untreated), which further suggests a role for CRTC1 in antidepressant response. Total Bdnf expression was then measured in WT and Crtc1 -/-mice (Fig. 2B ). In the HIP, genotype had a significant effect on Bdnf expression (F (1,27) =4.53, p=0.042), unlike desipramine that had no effect. Indeed, Crtc1 -/-mice had lower levels of Bdnf mRNA (p=0.044, vs. WT untreated) as previously observed in these animals (Breuillaud et al., 2012) . In the PFC, a significant effect of treatment was found (F (1, 22) (Fig. 2C) . No significant effect of genotype or treatment was observed in the PFC.
We were then interested in measuring Nr4a1-3 gene expression, as these orphan nuclear receptors are downregulated in Crtc1 -/-mice (Breuillaud et al., 2012) . Furthermore, NR4A1-3 have been shown to be involved in Bdnf regulation, in mood disorders and in neuroprotection (Schaffer et al., 2010; Volakakis et al., 2010; Volpicelli et al., 2007) . Analysis of Nr4a1 expression (Fig. 2D) Altogether, these data show that desipramine fails to induce the expression of Bdnf, Bdnf IV, Nr4a1 and Nr4a2 in the PFC and HIP of Crtc1 -/-mice, therefore possibly explaining their abnormal behavioral response to this antidepressant.
SAHA partially rescues the depressive-like phenotype of Crtc1 -/-mice
As CRTC1 is helping phosphorylated CREB to recruit the histone acetyltransferase CBP, we reasoned that HDAC inhibition might compensate for the possible deficit of CBP recruitment in
Crtc1
-/-mice, and thus rescue the expression of neuroplasticity genes involved in mood regulation. Moreover, several lines of evidence both in humans and in animal models have suggested that pathological conditions may alter the expression of Hdac family members, mainly of class I and IIa (Covington et al., 2009; Gräff et al., 2012; Han et al., 2014; Morris and Monteggia, 2013; Tsankova et al., 2006; Uchida et al., 2011) . Therefore, we first measured the expression of class I (Hdac1,2,3) and class IIa (Hdac4,5,7,9) members in the HIP and PFC of WT and Crtc1 -/-mice to determine whether mutant mice may present a possible altered epigenetic profile ( Fig. 3A and 3B ). We found that expression of most Hdac tested was globally unchanged in the HIP and PFC of Crtc1 -/-mice, except for Hdac9 that was slightly upregulated in the HIP of mutant mice (t=-4.29, df=10, p=0.002, vs. WT mice) (Fig. 3A) . However, this increased expression of Hdac9 in the HIP of Crtc1 -/-mice did not influence global acetylation of histone H3 and H4, as revealed by Western blot analysis (Fig. 3C-F) . This suggested that the behavioral and molecular phenotypes of Crtc1 -/-mice did not result from a major alteration of Hdac expression and histone acetylation.
HDAC inhibitors have been shown to have antidepressant effects in rodents and to regulate similar patterns of genes as antidepressants (Covington et al., 2009; Schroeder et al., 2007) .
SAHA is a hydroxamic acid compound that inhibits class I and II HDACs (Gräff and Tsai, 2013) .
Systemic administration of SAHA increases histone acetylation in the brain and has antidepressant effects in mice (Hockly et al., 2003; Uchida et al., 2011) . Moreover, in primary neuronal cultures, SAHA induces a rapid increase in histone acetylation at Bdnf promoters I and IV, and an upregulation of Bdnf expression (Koppel and Timmusk, 2013) . Therefore, SAHA was chosen to assess the behavioral response of WT and Crtc1 -/-mice to chronic HDAC inhibition.
We first controlled that an intraperitoneal injection of SAHA indeed triggered an increase of histone acetylation in the brain of WT and Crtc1 -/-mice ( Fig. 3C-F) . Acetyl-H3 and Acetyl-H4 signals were quantified and normalized over total H3 and total H4 signals. Analysis of histone H3 acetylation (Fig. 3C-D 
Crtc1 -/-vehicle).
Having shown that SAHA crosses the blood-brain barrier and increases histone acetylation in the brain, we then tested the behavioral response of WT and Crtc1 -/-mice to chronic SAHA treatment. Animals were first tested in the OSFS protocol ( Fig. 4A and 4B ). During the initial four consecutive days (from day -4 to -1), all groups showed an increase in their immobility time, with a significant interaction of time and genotype (F (3,96) 
SAHA partially restores normal gene expression in Crtc1 -/-mice
Gene expression analysis of Crtc1, Bdnf, BdnfIV and Nr4a1-3 was performed in order to investigate the effects of chronic SAHA on these genes (Fig. 5) . SAHA had no effect on Crtc1 expression in the HIP and PFC of WT mice (Fig. 5A) . A significant effect of genotype on total
Bdnf expression (Fig. 5B) (Fig. 5 , black bars) displayed several discrepancies, mostly in the HIP, as compared with those of mice that were exposed to the same behavioral paradigms, but not chronically injected (Fig. 2, black bars) . The most striking difference was the surprising increased Bdnf expression in the HIP of vehicle-injected Crtc1 -/-mice (Fig. 5B ). In addition, contrary to our previous observations and the results of (Fig. 5B ) appeared to be rather due to a decreased Bdnf expression in chronically injected WT mice (Fig. S1A) . Similarly, hippocampal
Nr4a1-3 levels seemed to be reduced mostly in WT mice chronically injected with vehicle ( Fig. 
S1C-E). With a few exceptions, Crtc1
-/-mice appeared to be less affected by this chronic injection stress, which might explain the inconsistent data of Figure 5 . In conclusion, the behavioral effect of chronic SAHA administration in Crtc1 -/-mice might be related to the restoration of normal Bdnf and BdnfIV expression in the PFC. However, unlike its effect in WT mice, chronic SAHA was not able to induce Nr4a1-3 expression in Crtc1 -/-mice, which suggests that the upregulation of these genes is not required to improve the behavioral despair of these animals in the OSFS paradigm.
Discussion
The generation and characterization of Crtc1 -/-mice highlighted a key role of CRTC1 as a mediator of neuroplasticity-related genes expression potentially involved in the pathophysiology of mood disorders (Breuillaud et al., 2012) . Moreover, we showed that CRTC1 is required for proper behavioral response to chronic fluoxetine treatment. In the present study, we further investigated the role of CRTC1 in behavioral and molecular response to antidepressants. We were first interested to assess the effect of another class of antidepressants. The tricyclic antidepressant desipramine was selected as this type of compounds mainly acts on the noradrenergic system, while fluoxetine is a selective serotonin reuptake inhibitor. We observed that Crtc1 -/-mice responded similarly to desipramine and fluoxetine; i.e. desipramine had no effect on these animals in the OSFS protocol, whereas it had anxiolytic effects in the NIH paradigm. These results further suggest that CRTC1 is involved in behavioral response to antidepressants, mainly in behavioral despair-related paradigms, and that both noradrenergic and serotonergic pathways activated by antidepressants converge on CRTC1. We also observed that desipramine induced the expression of Crtc1 in the PFC of WT mice, which strengthens the hypothesis of a pivotal role of CRTC1 in antidepressant response.
Interestingly, desipramine, like fluoxetine in our previous study, still elicited behavioral response in Crtc1 -/-mice in the NIH paradigm. This test has the advantage to be sensitive to chronic, but not acute antidepressant treatment. However, hyponeophagic behavior can be related to depressive but also anxious behavior (Dulawa and Hen, 2005) and both fluoxetine and desipramine have anxiolytic effects (Zohar and Westenberg, 2000) . Therefore, the behavioral response of Crtc1 -/-mice observed in the NIH might be due to the anxiolytic effects of these treatments. The fact that these drugs still have anxiolytic effect in the absence of CRTC1 suggests that these effects are either CRTC1-independent, or that alternative pathways can be used to counteract the absence of CRTC1.
Gene expression analyses revealed that desipramine induced the expression of Bdnf, BdnfIV, Nr4a1, and Nr4a2 in the HIP and PFC of WT mice, but failed to do so in Crtc1 -/-mice. While desipramine has been known for a long time to induce the expression of Bdnf (Nibuya et al., 1995) , we report here that it also induces the expression of Nr4a1 and Nr4a2, which have been linked with mood disorders and Bdnf regulation (Buervenich et al., 2000; Volpicelli et al., 2007; Xing et al., 2006) . Furthermore, we show that CRTC1 is required for the induction of Nr4a1 and Nr4a2 by chronic desipramine, thus suggesting a role for these nuclear receptors in the behavioral response to antidepressants.
Considering this hypothesis, we attempted to counteract CRTC1 deletion and restore normal gene expression in Crtc1 -/-mice by treating them with a HDAC inhibitor. Epigenetic gene regulation has been widely shown to be involved in mood disorders. Mechanisms such as DNA methylation and histone acetylation (mechanisms that respectively repress and activate gene transcription) were found to be altered in depressed patients and in response to chronic stress (Sun et al., 2013; Vialou et al., 2013) . Antidepressants also induce epigenetic changes, such as histone H3 hyperacetylation (Tsankova et al., 2006) . HDAC inhibitors were found to have antidepressant effects in rodents, and to regulate a subset of genes in a similar way as antidepressants drugs (Covington et al., 2009; Schroeder et al., 2007; Uchida et al., 2011) . Of particular interest for this study, Bdnf and Nr4a1-3 have been shown to be induced by HDAC inhibitors (Hawk et al., 2012; Schroeder et al., 2007; Vecsey et al., 2007) . In the light of these results, we injected intraperitoneally the HDAC inhibitor SAHA to WT and Crtc1 -/-mice, and confirmed that a systemic administration of SAHA increased histone acetylation in the brain.
Mutant mice responded to chronic SAHA in the OSFS paradigm, as their immobility time decreased over time, indicating a successful antidepressant effect of SAHA in these animals.
However, the effect was not complete, as treated Crtc1 -/-mice did not reach the level of WT animals. This suggests that SAHA was not able to completely rescue the depressive-like behavior of these animals. It is important to keep in mind that Crtc1 -/-mice are complete knock-out animal, therefore developmental effects of CRTC1 deficiency cannot be excluded.
Thus, some behavioral and molecular impairment might not be completely reversible, and might explain the partial behavioral effects of SAHA. Nevertheless, this result indicates that the depressive-like behavior of Crtc1 -/-mice can be partially rescued by acting at the epigenetic level.
In the NIH, the effect of SAHA was less clear. While it reduced the latency of WT mice, it only produced a trend to a decreased latency in Crtc1 -/-mice. However, basal latency of vehicletreated WT animals was abnormally high, which might indicate that the animals had higher basal anxiety, as compared with the NIH experiment of Fig. 1C . This might be explained by a possible effect of the three-week stressful OSFS procedure combined with chronic injections.
All in all, NIH results suggest that SAHA had no effect on the anxiety of Crtc1 -/-mice, yet as WT animals seemed to present unusual higher anxiety, results of this test should be taken with caution.
Molecular investigation of SAHA effects allowed us to better understand the behavioral effects of this treatment on Crtc1 -/-mice. In the PFC, the decreased Bdnf and BdnfIV expression was successfully rescued by SAHA treatment. This rescue of Bdnf expression may be related to the decreased immobility of Crtc1 -/-mice in the OSFS, as BDNF alterations have often been linked with behavioral despair (Borsoi et al., 2014; Koponen et al., 2005; Shirayama et al., 2002; Siuciak et al., 1997) . While no effect of SAHA was observed in the HIP, Crtc1 -/-mice elusively displayed higher Bdnf expression in this structure, instead of their usual lower levels. The comparison of Bdnf levels in control groups of WT and Crtc1 -/-mice of Figure 2 and 5 suggested that the stress generated by chronic daily vehicle injections decreased Bdnf expression only in WT and not in Crtc1 -/-mice (Fig. S1 ). While it is generally suggested that acute and chronic stress decrease Bdnf expression (Duman and Monteggia, 2006) , several studies have shown opposite findings (Charrier et al., 2006; Marmigere et al., 2003; Nair et al., 2007) , thus revealing a complex interplay between stress and BDNF. Crtc1 -/-mice might thus present an altered reactivity to stress, evidenced by differential Bdnf regulation. This highlights again the importance of CRTC1 in the regulation of Bdnf and stress response, and should be a focus for future investigations.
Interestingly, SAHA was found to increase Nr4a1-3 expression in the HIP and/or PFC of WT mice, which could be correlated with its antidepressant effect in these mice. This is in line with previous studies showing that HDAC inhibitors increase Nr4a1-3 expression via the CREB-CBP pathway, which is a key mechanism for memory enhancement (Hawk et al., 2012; Vecsey et al., 2007) . However, SAHA treatment was not able to increase Nr4a1-3 expression in Crtc1 -/-mice, and therefore these genes are apparently not involved in the partial rescue of their depressivelike behavior. These results suggest that CRTC1 is required for the CREB-CBP-mediated Nr4a1-3 transcription induced by HDAC inhibitors. As this pathway is involved in learning processes, these findings are in keeping with the recently characterized important role of CRTC1 in memory and cognitive behavior (Nonaka et al., 2014a; Nonaka et al., 2014b; Parra-Damas et al., 2014) . Further characterization of cognitive and learning behaviors of Crtc1 -/-mice should better characterize CRTC1 function in these processes.
Conclusions
In this study, we provide evidence that CRTC1 is a key regulator of behavioral and molecular response to antidepressant. We show that CRTC1 is required for complete behavioral antidepressant response and for desipramine-induced expression of Bdnf and Nr4a1-2. By acting downstream of CRTC1, the HDAC inhibitor SAHA improves the depressive-like behavior of Crtc1 -/-mice. This partial rescue was paralleled by a restoration of Bdnf expression in the PFC, whereas SAHA was unable to increase Nr4a1-3 expression in these mice, thus suggesting that these orphan nuclear receptors do not play a major role in the improvement of their depressive-like behavior. In conclusion, several lines of evidence strongly suggest that CRTC1-deficient mice are a valuable animal model of depressive phenotypes and treatment resistance.
As an important regulatory mediator of depression-related genes, CRTC1 provide a new focus for future research aiming at a better understanding of depression and new therapeutic approaches. paradigm. Latencies to drink sweetened condensed milk are shown in the homecage and in the novel environment. Two mice were removed for having latency scores > 2 SD from the mean.
Figure Legends
One mouse was removed for never having drunk the milk during the habituation and test phases. In the homecage conditions, no effect of SAHA was observed in any groups. In the novel environment, SAHA-treated mice (n=7) presented significant shorter latencies to drink the milk, as compared to vehicle-treated WT mice (n=8) (*p<0.05, vs. WT Vehicle). SAHA-treated Crtc1 -/-mice showed a non-significant trend to a shorter latency than vehicle-treated Crtc1 -/-mice (n=8 for each group). Data are means ±SEM. SAHA had no effect on Crtc1 expression in the HIP and PFC of WT mice (n=8 for both group . SAHA had no effect on Nr4a2 expression in Crtc1 -/-mice but increased its expression in the HIP and PFC of WT mice (*p<0.05, vs. WT Vehicle). (F) SAHA had no effect on Nr4a3 expression in the HIP of all groups.
In the PFC, SAHA increased Nr4a3 expression of WT animal but had no effect on Crtc1 -/-mice (*p<0.05, vs. WT Vehicle). Data are mean ±SEM. 
